1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Moses makes his mark

 
• By Jo Shorthouse

Last year was transformational for the Belgian biotech Ablynx. Not only did it sign the biggest product licensing deal of 2013 with AbbVie, it also further expanded its relationship with Merck Serono through a fourth collaboration; its first venture investors Gimv and Sofinnova Partners exited the company; and the firm took its first foray into the emerging markets via a $2m deal with China's Eddingpharm.

Last year was transformational for the Belgian biotech Ablynx. Not only did it sign the biggest product licensing deal of 2013 with AbbVie, it also further expanded its relationship with Merck Serono through a fourth collaboration; its first venture investors Gimv and Sofinnova Partners exited the company; and the firm took its first foray into the emerging markets via a $2m deal with China's Eddingpharm.

As such, one might mistakenly think that 2014 would be a good time for the management of Ablynx, a biotech which discovers and develops nanobodies, to take a breath....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

More from Therapy Areas

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback